Pharmaceutical

LXE-408 by Novartis for Chagas Disease (American Trypanosomiasis): Likelihood of Approval

LXE-408 is under clinical development by Novartis and currently in Phase I for Chagas Disease (American Trypanosomiasis).

Dec 31, 2024 - 06:00
LXE-408 is under clinical development by Novartis and currently in Phase I for Chagas Disease (American Trypanosomiasis).
Read the original article

Tags:

Previous Article

Tebapivat by Agios Pharmaceuticals for Sickle Cell Disease: Likelihood of Approval

Next Article

Xaluritamig by Amgen for Prostate Cancer: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Bavarian Nordic shares sink by 12% after mpox sales slump in Q3

Bavarian Nordic shares sink by 12% after mpox sales slu...

Nov 17, 2024

Roche relaunches refillable wet AMD implant two years after recall

Roche relaunches refillable wet AMD implant two years a...

Jul 10, 2024

Black men were likely underdiagnosed with lung problems because of bias in software, study suggests

Black men were likely underdiagnosed with lung problems...

Jun 2, 2023